Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver ...

Welcome to our weekly Search Engine Land series, Everything you need to know about Google Ads in less than 3 minutes. Every Wednesday, I’m highlighting a different Google Ads feature, and what you ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

How often have you heard, “Use broad match along with smart bidding to get the best results?” Broad match can learn based on previous conversion activity. It can also use previous user search data, ...

In this week’s PPC Pulse: updates include an inventory expansion for Apple Ads, and Google confirms that Exact match keywords are not eligible to serve for Ads in AI Overviews. Apple announced ...